Resumen de Real‑world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early‑stage HER2‑positive breast cancer: the NEOPERSUR study
Alejandro Falcón González, Javier Salvador Boffil, M. Ruiz Borrego, Josefina Cruz Jurado, Rocío Álvarez Ambite, Elisenda Llabres Valentí, Rocío Urbano Cubero, Dina Mohamed Ahmed Samir Elkahwagy, María del Carmen Álamo de la Gala, F. Henao Carrasco, Antonia Martínez Guisado, Carlos José Rodríguez González, Marta Amérigo Góngora, Juan Bayo Calero, Lourdes Rodríguez Pérez, Pilar López Álvarez, E. González Flores, María Valero Arbizu, Alicia Quílez Cutillas, Eloísa Rubio Pérez
Purpose HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as demonstrated in neoadjuvant trials. This study aims to provide real-world evidence on the use and effectiveness of combined pertuzumab, trastuzumab and chemotherapy (CT) in early-stage HER2-positive BC.
Methods A retrospective, multicentre study was conducted on patients diagnosed with HER2-positive early BC treated with neoadjuvant pertuzumab and trastuzumab plus CT at 13 Spanish sites. The primary endpoint was pathological complete response (pCR).
Results A total of 310 patients were included. Pertuzumab and trastuzumab were combined with anthracyclines and taxanes, carboplatin and docetaxel, and taxane-based CT in 77.1%, 16.5%, and 6.5% of patients, respectively. Overall, the pCR rate was 62.2%. The pCR was higher amongst patients with hormone receptor-negative tumours and with tumours expressing higher levels of Ki-67 (> 20%). After postoperative adjuvant treatment, 13.9% of patients relapsed. Those patients who did not achieve pCR, with tumours at advanced stages (III), and with node-positive disease were more likely to experience distant relapse. Median overall survival (OS) and distant disease-free survival (D-DFS) were not reached at the study end. The estimated mean OS and D-DFS times were 7.5 (95% CI 7.3–7.7) and 7.3 (95% CI 7.1–7.5) years, respectively (both were significantly longer amongst patients who achieved pCR). Grade 3–4 anti-HER2 related toxicities were reported in six (1.9%) patients.
Conclusion Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2- positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.
